Articles From: Nuvo Research announces 2013 First Quarter Results to NVHomes Announces Grand Opening for the New Empress Model at Autumn River in Ellicott City, MD


2013/5/1
MISSISSAUGA, ON , May 1, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the first quarter ended March 31, 2013 .
Sign-up for Nuvo Research announces 2013 First Quarter Results investment picks
2013/5/1
Nuvo Research announces 2013 First Quarter Results Canada NewsWire MISSISSAUGA, ON, May 1, 2013 /CNW/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the first quarter ended March 31, 2013 .
Sign-up for Nuvo Research announces 2013 First Quarter Results investment picks
2013/4/23
Nuvo Research Inc. (TSX:NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology.
Sign-up for Nuvo Research Announces European Launch of Pliaglis® by Galderma investment picks
2013/4/23
Nuvo Research announces European launch of Pliaglis® by Galderma Canada NewsWire MISSISSAUGA, ON, April 23, 2013 /CNW/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%.  Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology.
Sign-up for Nuvo Research announces European launch of Pliaglis® by Galderma investment picks
2013/4/23
MISSISSAUGA, ON , April 23, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%.  Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology.
Sign-up for Nuvo Research announces European launch of Pliaglis® by Galderma investment picks
2013/3/5
Nuvo Research announces FDA response to PENNSAID® 2% NDA Canada NewsWire MISSISSAUGA, ON, March 5, 2013 /CNW/ - Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that its U.S. licensing partner, Mallinckrodt, the Pharmaceuticals Business of Covidien (NYSE:COV) , has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following the review of Mallinckrodt's New Drug Application (NDA) for diclofenac sodium topical solution, 2% w/w (PENNSAID 2%). In the letter, the FDA requires that Mallinckrodt successfully complete a pharmacokinetic study comparing PENNSAID 2% to original PENNSAID 1.5%. Similar pharmacokinetic studies submitted by Mallinckrodt with the NDA were not acceptable to the FDA because reserve samples were not retained at the clinical site.
Sign-up for Nuvo Research announces FDA response to PENNSAID® 2% NDA investment picks
2013/3/5
MISSISSAUGA, ON , March 5, 2013 /PRNewswire/ - Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that its U.S. licensing partner, Mallinckrodt , the Pharmaceuticals Business of Covidien (NYSE:COV) , has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following the review of Mallinckrodt's New Drug Application (NDA) for diclofenac sodium topical solution, 2% w/w (PENNSAID 2%). In the letter, the FDA requires that Mallinckrodt successfully complete a pharmacokinetic study comparing PENNSAID 2% to original PENNSAID 1.5%. Similar pharmacokinetic studies submitted by Mallinckrodt with the NDA were not acceptable to the FDA because reserve samples were not retained at the clinical site.
Sign-up for Nuvo Research announces FDA response to PENNSAID® 2% NDA investment picks
2013/5/9
Nuvo Research announces notice of Intention to Grant a European Patent for PENNSAID® 2% Canada NewsWire Forward-Looking Statements Certain statements in this news release constitute forward-looking statements within the meaning of applicable securities laws.
Sign-up for Nuvo Research announces notice of Intention to Grant a European Patent for PENNSAID® 2% investment picks
2013/5/9
MISSISSAUGA, ON , May 9, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that the European Patent Office has issued a notice of Intention to Grant a European Patent that provides protection for the Company's PENNSAID ® 2% product.
Sign-up for Nuvo Research announces notice of Intention to Grant a European Patent for PENNSAID® 2% investment picks
2013/4/19
Nuvo Research announces scientific presentation at the Annual Meeting of the American Medical Society for Sports Medicine Canada NewsWire Data Evaluating Synera ® for the Treatment of Shoulder Impingement Syndrome MISSISSAUGA, ON, April 19, 2013 /CNW/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that researchers presented scientific data related to Synera ® (70 mg lidocaine/ 70 mg tetracaine) topical patch at the 22 nd Annual Meeting of the American Medical Society for Sports Medicine (AMSSM) in San Diego , California.
Sign-up for Nuvo Research announces scientific presentation at the Annual Meeting of the American Medical Society for Sports Medicine investment picks
2013/4/19
Data Evaluating Synera ® for the Treatment of Shoulder Impingement Syndrome MISSISSAUGA, ON , April 19, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that researchers presented scientific data related to Synera ® (70 mg lidocaine/ 70 mg tetracaine) topical patch at the 22 nd Annual Meeting of the American Medical Society for Sports Medicine (AMSSM) in San Diego, California .
Sign-up for Nuvo Research announces scientific presentation at the Annual Meeting of the American Medical Society for Sports Medicine investment picks
2013/1/29
Nuvo Research announces settlement agreement with Apotex in PENNSAID® generic litigation Canada NewsWire MISSISSAUGA, ON, Jan.
Sign-up for Nuvo Research announces settlement agreement with Apotex in PENNSAID® generic litigation investment picks
2013/1/29
MISSISSAUGA, ON , Jan.
Sign-up for Nuvo Research announces settlement agreement with Apotex in PENNSAID® generic litigation investment picks
2013/3/11
Nuvo Research announces U.S. launch of Pliaglis® by Galderma Canada NewsWire Important Safety Information Indication: PLIAGLIS® (lidocaine and tetracaine) Cream 7% / 7% is indicated for use on intact skin in adults to provide topical local analgesia for superficial dermatological procedures such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal.
Sign-up for Nuvo Research announces U.S. launch of Pliaglis® by Galderma investment picks
2013/3/11
MISSISSAUGA, ON , March 11, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Laboratories, L.P., the U.S. affiliate of Galderma Pharma, S.A. (Galderma), today announced the U.S. launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%.  Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology.
Sign-up for Nuvo Research announces U.S. launch of Pliaglis® by Galderma investment picks
2013/3/18
MISSISSAUGA, ON , March 18, 2013 /PRNewswire/ - Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that a Question and Answer document has been posted on its website to provide additional information to Nuvo shareholders regarding the regulatory status of Pennsaid 2% in the United States .
Sign-up for Nuvo Research provides additional information regarding Pennsaid 2% investment picks
2013/5/7
MISSISSAUGA, ON , May 7, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) (the "Company" or "Nuvo"), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced that it will proceed with its proposed share consolidation (the "Consolidation"), as approved by the shareholders of Nuvo at the annual and special meeting held on May 15, 2012 , on the basis of 65 pre-Consolidation common shares for one (1) post-Consolidation common share.
Sign-up for Nuvo Research to Complete Share Consolidation investment picks
2013/5/7
Nuvo Research to Complete Share Consolidation Canada NewsWire MISSISSAUGA, ON, May 7, 2013 /CNW/ - Nuvo Research Inc. (TSX: NRI) (the "Company" or "Nuvo"), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced that it will proceed with its proposed share consolidation (the "Consolidation"), as approved by the shareholders of Nuvo at the annual and special meeting held on May 15, 2012 , on the basis of 65 pre-Consolidation common shares for one (1) post-Consolidation common share.
Sign-up for Nuvo Research to Complete Share Consolidation investment picks
2013/2/7
LAS VEGAS , Feb.
Sign-up for NV Energy Increases Quarterly Dividend 12 Percent investment picks
2013/4/18
SEPA Announces Annual Ranking of Utility Solar Integration WASHINGTON , April 18, 2013 /PRNewswire/ -- NV Energy, Inc. (NYSE: NVE) and the Solar Electric Power Association (SEPA) today announced that NV Energy has been recognized as a national leader in the integration and delivery of solar-based renewable solutions.
Sign-up for NV Energy Receives Industry Recognition for Solar Energy Adoption investment picks
2013/5/3
Highlights: - Earnings aided by weather, lower costs - Earnings guidance of $1.25 to $1.35 per share for 2013 reaffirmed - NV Energize smart grid project nearing completion - ON Line transmission project on track for year-end 2013 completion LAS VEGAS , May 3, 2013 /PRNewswire/ -- NV Energy, Inc. (NYSE: NVE) today announced financial results for the three months ended March 31, 2013 as shown in the table below.
Sign-up for NV Energy Reports Financial Results for First Quarter 2013 investment picks
2013/2/22
Highlights: -- Favorable fourth quarter results despite mild weather -- 12-month results in line with earnings guidance --
Sign-up for NV Energy Reports Fourth Quarter and Full Year 2012 Results; Announces 2013 Earnings Guidance investment picks
2013/2/5
LAS VEGAS , Feb.
Sign-up for NV Energy Supported More Than 400 Nonprofits Statewide in 2012 with $6.1 Million in Funding investment picks
2013/4/22
LAS VEGAS , April 22, 2013 /PRNewswire/ -- Senior management of NV Energy, Inc. (NYSE: NVE) will review the company's first quarter 2013 financial results and other matters during a conference call and webcast on Friday, May 3 , at 7 a.m. Pacific Daylight Time .
Sign-up for NV Energy to Report Financial Results on May 3 investment picks
2013/5/8
LAS VEGAS , May 8, 2013 /PRNewswire/ -- NV Energy, Inc. (NYSE: NVE) announced that its board of directors today declared a cash dividend of $0.19 per share, payable on June 19, 2013 to shareholders of record on June 4, 2013 .
Sign-up for NV Energy, Inc. Announces Quarterly Dividend investment picks
2013/1/29
GEORGE MASON MORTGAGE, a subsidiary of Cardinal Bank (NASDAQ: CFNL) , is pleased to announce that Lender Matt Fox has been named “Associate of the Year” by the Northern Virginia Building Industry Association (NVBIA). The prestigious award was announced at the annual President’s Ball, an event which celebrates the accomplishments of the past year and acknowledges the “best of the best” within the trade association's membership.
Sign-up for NVBIA Names George Mason Mortgage’s Matt Fox 2012 "Associate of the Year" investment picks
2013/5/1
EDEN PRAIRIE, Minn., May 1, 2013 (GLOBE NEWSWIRE) -- NVE Corporation (Nasdaq:NVEC) announced today financial results for the quarter and fiscal year ended March 31, 2013.
Sign-up for NVE Corporation Reports Fourth Quarter and Fiscal Year Results investment picks
2013/4/22
EDEN PRAIRIE, Minn., April 22, 2013 (GLOBE NEWSWIRE) -- NVE Corporation (Nasdaq:NVEC) announced that it plans to release its financial results for the quarter and fiscal year ended March 31, 2013 on Wednesday, May 1, 2013 after the close of the Nasdaq Regular Market.
Sign-up for NVE Schedules Conference Call on Fourth Quarter and Fiscal Year Results investment picks
2013/2/1
ELLICOTT CITY, Md.
Sign-up for NVHomes Announces Grand Opening for the New Empress Model at Autumn River in Ellicott City, MD investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Nuvo Research announces 2013 First Quarter Results to NVHomes Announces Grand Opening for the New Empress Model at Autumn River in Ellicott City, MD
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity